Who was studied?
132 patients pooled across PRaG studies, with validation data from additional registered cohorts.
What does the publication report?
The reported model achieved ROC AUC 0.818 in model evaluation and 0.801 in independent validation.
Safety findings
This efficacy-prediction abstract does not provide a new graded safety analysis.
How should we interpret it?
Retrospective modeling reported as a conference abstract. Model discrimination does not establish clinical decision benefit; pooled patients overlap with source trials.
Read the original source
This independently written summary was checked against the publicly available abstract. Selected figures, where included, are checked against the full publication. This is not a full-paper translation or a clinical recommendation.
Novel dynamic circulating biomarkers for predicting therapeutic efficacy of PRaG regimen in advanced refractory solid tumors. · DOI: 10.1200/JCO.2025.43.16_suppl.2548
Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.